{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "marketState": "REGULAR", "regularMarketChangePercent": 0.1724095, "regularMarketPrice": 2.905, "exchange": "NGM", "shortName": "Eliem Therapeutics, Inc", "longName": "Eliem Therapeutics, Inc.", "messageBoardId": "finmb_603195850", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1628602200000, "priceHint": 4, "regularMarketChange": 0.004999876, "regularMarketTime": 1684257328, "regularMarketDayHigh": 2.91, "regularMarketDayRange": "2.64 - 2.91", "regularMarketDayLow": 2.64, "regularMarketVolume": 7451, "regularMarketPreviousClose": 2.9, "bid": 2.7, "ask": 3.05, "bidSize": 13, "askSize": 22, "fullExchangeName": "NasdaqGM", "financialCurrency": "USD", "regularMarketOpen": 2.906, "averageDailyVolume3Month": 16881, "averageDailyVolume10Day": 6420, "fiftyTwoWeekLowChange": 0.69499993, "fiftyTwoWeekLowChangePercent": 0.3144796, "fiftyTwoWeekRange": "2.21 - 5.2", "fiftyTwoWeekHighChange": -2.2949998, "fiftyTwoWeekHighChangePercent": -0.44134614, "fiftyTwoWeekLow": 2.21, "fiftyTwoWeekHigh": 5.2, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.48, "epsForward": -0.73, "epsCurrentYear": -1.03, "priceEpsCurrentYear": -2.8203883, "trailingAnnualDividendRate": 0.0, "sharesOutstanding": 26973900, "bookValue": 4.845, "fiftyDayAverage": 3.2059, "fiftyDayAverageChange": -0.30089998, "fiftyDayAverageChangePercent": -0.0938582, "twoHundredDayAverage": 3.16768, "twoHundredDayAverageChange": -0.26268005, "twoHundredDayAverageChangePercent": -0.08292506, "marketCap": 91092376, "forwardPE": -3.979452, "priceToBook": 0.5995872, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-08-10", "displayName": "Eliem Therapeutics", "symbol": "ELYM"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "23515 NE Novelty Hill Road", "address2": "Suite B221 #125", "city": "Redmond", "state": "WA", "zip": "98053", "country": "United States", "phone": "877 354 3689", "website": "https://eliemtx.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.", "fullTimeEmployees": 30, "companyOfficers": [{"maxAge": 1, "name": "Dr. Andrew  Levin M.D., Ph.D.", "age": 45, "title": "Principal Financial Officer & Exec. Chairman", "yearBorn": 1977, "fiscalYear": 2022, "totalPay": {"raw": 73000, "fmt": "73k", "longFmt": "73,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Valerie  Morisset Ph.D.", "age": 52, "title": "Chief Scientific Officer and Exec. VP of R&D", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 617865, "fmt": "617.87k", "longFmt": "617,865"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 879225, "fmt": "879.23k", "longFmt": "879,225"}}, {"maxAge": 1, "name": "Ms. Emily  Pimblett", "age": 38, "title": "Principal Accounting Officer", "yearBorn": 1984, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Jo  Palmer-Phillips Ph.D.", "title": "Chief Devel. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mark  Versavel M.B.A., M.D., MBA, Ph.D.", "age": 63, "title": "Sr. VP & Chief Medical Officer", "yearBorn": 1959, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}